Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.

Chao BN, Baldwin WH, Healey JF, Parker ET, Shafer-Weaver K, Cox C, Jiang P, Kanellopoulou C, Lollar P, Meeks SL, Lenardo MJ.

J Thromb Haemost. 2016 Feb;14(2):346-55. doi: 10.1111/jth.13202. Epub 2016 Jan 8.

2.

Professional development session for early career scientists at SITC 2012.

Capitini CM, Redmond WL, Shafer-Weaver KA.

J Immunother Cancer. 2013 Jun 27;1:6. doi: 10.1186/2051-1426-1-6. eCollection 2013.

3.

Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status.

Lo B, Swafford AD, Shafer-Weaver KA, Jerome LF, Rakhlin L, Mathern DR, Callahan CA, Jiang P, Davison LJ, Stevens HE, Lucas CL, White J, von Borstel R, Todd JA, Lenardo MJ.

J Transl Med. 2011 Nov 28;9:203. doi: 10.1186/1479-5876-9-203.

4.

HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors.

Zielinski R, Lyakhov I, Hassan M, Kuban M, Shafer-Weaver K, Gandjbakhche A, Capala J.

Clin Cancer Res. 2011 Aug 1;17(15):5071-81. doi: 10.1158/1078-0432.CCR-10-2887. Epub 2011 Jul 26.

5.

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.

Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, Ambs S, Yagita H, Hurwitz AA.

J Clin Invest. 2011 Apr;121(4):1361-72. doi: 10.1172/JCI44325. Epub 2011 Mar 23. Retraction in: J Clin Invest. 2015 May;125(5):2179.

6.

Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.

Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA.

J Immunol. 2009 Oct 15;183(8):4848-52. doi: 10.4049/jimmunol.0900848.

7.

Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.

Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, Greenberg NM, Hurwitz AA.

Cancer Res. 2009 Aug 1;69(15):6256-64. doi: 10.1158/0008-5472.CAN-08-4516. Epub 2009 Jul 21. Retraction in: Cancer Res. 2016 Apr 15;76(8):2490.

8.

Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials.

Zaritskaya L, Shafer-Weaver KA, Gregory MK, Strobl SL, Baseler M, Malyguine A.

J Immunother. 2009 Feb-Mar;32(2):186-94. doi: 10.1097/CJI.0b013e318197b1b2.

PMID:
19238018
9.

T cell tolerance to tumors and cancer immunotherapy.

Shafer-Weaver K, Anderson M, Malyguine A, Hurwitz AA.

Adv Exp Med Biol. 2007;601:357-68. Review.

PMID:
17713024
10.

New approaches for monitoring CTL activity in clinical trials.

Malyguine A, Strobl S, Zaritskaya L, Baseler M, Shafer-Weaver K.

Adv Exp Med Biol. 2007;601:273-84. Review.

PMID:
17713015
11.

Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer.

Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA.

J Immunol. 2007 Feb 1;178(3):1268-76. Erratum in: J Immunol. 2007 Nov 15;179(10):7184.

12.

Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials.

Shafer-Weaver K, Rosenberg S, Strobl S, Gregory Alvord W, Baseler M, Malyguine A.

J Immunother. 2006 May-Jun;29(3):328-35.

PMID:
16699376
13.

A novel flow cytometric assay for evaluating cell-mediated cytotoxicity.

Burkett MW, Shafer-Weaver KA, Strobl S, Baseler M, Malyguine A.

J Immunother. 2005 Jul-Aug;28(4):396-402.

PMID:
16000959
14.
15.

IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells.

Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM.

J Immunol. 2004 Dec 15;173(12):7170-82.

16.

Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay.

Shafer-Weaver KA, Sayers T, Kuhns DB, Strobl SL, Burkett MW, Baseler M, Malyguine A.

J Transl Med. 2004 Sep 20;2(1):31.

17.

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets.

Malyguine A, Strobl SL, Shafer-Weaver KA, Ulderich T, Troke A, Baseler M, Kwak LW, Neelapu SS.

J Transl Med. 2004 Mar 29;2(1):9.

18.

The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity.

Shafer-Weaver K, Sayers T, Strobl S, Derby E, Ulderich T, Baseler M, Malyguine A.

J Transl Med. 2003 Dec 29;1(1):14.

19.

Immune surveillance of mammary tissue by phagocytic cells.

Paape MJ, Shafer-Weaver K, Capuco AV, Van Oostveldt K, Burvenich C.

Adv Exp Med Biol. 2000;480:259-77. Review.

PMID:
10959434
20.
21.

Immunobiology of the mammary gland.

Sordillo LM, Shafer-Weaver K, DeRosa D.

J Dairy Sci. 1997 Aug;80(8):1851-65. Review.

22.

Bovine CD8+ suppressor lymphocytes alter immune responsiveness during the postpartum period.

Shafer-Weaver KA, Sordillo LM.

Vet Immunol Immunopathol. 1997 May;56(1-2):53-64.

PMID:
9220580
23.

Enhancing bactericidal activity of bovine lymphoid cells during the periparturient period.

Shafer-Weaver KA, Sordillo LM.

J Dairy Sci. 1996 Aug;79(8):1347-52.

24.

Diminished mammary gland lymphocyte functions parallel shifts in trafficking patterns during the postpartum period.

Shafer-Weaver KA, Pighetti GM, Sordillo LM.

Proc Soc Exp Biol Med. 1996 Jul;212(3):271-80.

PMID:
8677273

Supplemental Content

Loading ...
Support Center